Microsatellite pedigree reconstruction provides evidence that ‘Müller-Thurgau’ is a grandson of ‘Pinot’ and ‘Schiava Grossa’

‘Müller-Thurgau’ has recently been proven to be a cross between ‘Riesling’ and ‘Madeleine Royale’, a 19th century cross whose parents are unknown. Parentage analysis based on 93 grape cultivars of central Europe genotyped at 57 microsatellites provides here evidence that ‘Madeleine Royale’ = ‘Pinot’ × ‘Schiava Grossa’. Since ‘Riesling’ is known to be a progeny of ‘Gouais Blanc’, ‘Müller-Thurgau’ is therefore a grandchild of ‘Pinot’ (either ‘Pinot’ noir, gris or blanc), ‘Schiava Grossa’ (or ‘Frankenthaler’ or ‘Trollinger’) and ‘Gouais Blanc’ (or ‘Heunisch Weiss’)

Identity and parentage of two alpine grape cultivars from Switzerland (Vitis vinifera L. Lafnetscha and Himbertscha)

Four closely related white grape cultivars from the Western Alps (Switzerland) - Humagne Blanc, Completer, Lafnetscha and Himbertscha - and three putative relatives or synonyms - Gouais Blanc, Plantscher and Bordeaux Blanc - were analyzed with up to 50 microsatellite markers. Humagne Blanc and Completer are ancient cultivars from the Haut-Valais and Graubünden regions, respectively. Lafnetscha and Himbertscha are lesser-known cultivars scarcely cultivated in Haut-Valais. Lafnetscha is frequently considered as synonym of Completer. Himbertscha might be related to Gouais Blanc, one of the parents of Chardonnay, Gamay, etc. Plantscher, a putative synonym of Lafnetscha, is scarcely cultivated in Haut-Valais (Switzerland) and Bordeaux Blanc (or Gros Bourgogne) is a cultivar of unknown origin (despite its names) cultivated in Switzerland. Our results allowed us to determine the true-to-type Lafnetscha and confirmed that Lafnetscha is not a synonym of Completer. Plantscher is not a synonym of Lafnetscha but a synonym of Bordeaux Blanc (or Gros Bourgogne) and is a likely parent or progeny of the Hungarian Furmint. Himbertscha is not related to Gouais Blanc and shares at least one allele at each locus with Humagne Blanc, providing strong evidence of a parent/progeny relationship. Given that Humagne Blanc is an older cultivar, we propose that it is the parent of Himbertscha. Alleles at 49 out of 50 microsatellite loci are consistent with Lafnetscha being the progeny of Completer and Humagne Blanc. The exception is a 10-base pair discrepancy at one locus (VVMD 36), most likely due to the occurrence of a null allele, since this parentage is supported at other markers by very high likelihood ratios. With Lafnetscha = Completer x Humagne Blanc, we present the second grape cultivar parentage showing a multiple repeat discrepancy at one locus. This study emphasizes that one multiple repeat unit discrepancy is not sufficient to reject a parentage, and that the greater is the number of loci, the greater are the chances to encounter null alleles or clonal mutations

A positive interaction between inhibitors of protein synthesis and cefepime in the fight against methicillin-resistant Staphylococcus aureus

Quinupristin-dalfopristin (Q-D) synergizes with cefepime for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). Here, we studied whether the synergism was restricted to MRSA and if it extended to non-beta-lactam cell wall inhibitors or to other inhibitors of protein synthesis. Three MRSA and two methicillin-susceptible S. aureus (MSSA) strains were tested, including an isogenic pair of mecA −/mecA + S. aureus Newman. The drug interactions were determined by fractional inhibitory concentration (FIC) indices and population analysis profiles. The antibacterial drugs that we used included beta-lactam (cefepime) and non-beta-lactam cell wall inhibitors (D-cycloserine, fosfomycin, vancomycin, teicoplanin), inhibitors of protein synthesis (Q-D, erythromycin, chloramphenicol, tetracycline, linezolid, fusidic acid), and polynucleotide inhibitors (cotrimoxazole, ciprofloxacin). The addition of each protein inhibitor to cefepime was synergistic (FIC ≤ 0.5) or additive (FIC > 0.5 but < 1) against MRSA, but mostly indifferent against MSSA (FIC ≥ 1 but ≤ 4). This segregation was not observed after adding cotrimoxazole or ciprofloxacin to cefepime. Population analysis profiles were performed on plates in the presence of increasing concentrations of the cell wall inhibitors plus 0.25 × minimum inhibitory concentration (MIC) of Q-D. Cefepime combined with Q-D was synergistic against MRSA, but D-cycloserine and glycopeptides were not. Thus, the synergism was specific to beta-lactam antibiotics. Moreover, the synergism was not lost against fem mutants, indicating that it acted at another level. The restriction of the beneficial effect to MRSA suggests that the functionality of penicillin-binding protein 2A (PBP2A) was affected, either directly or indirectly. Further studies are necessary in order to provide a mechanism for this positive interactio

Genetic relationships among local Vitis vinifera cultivars from Campania (Italy)

A total of 114 accessions putatively corresponding to 69 local grape cultivars from Campania (Southern Italy) were analysed with 8 microsatellite markers (VVS2, VVMD5, VVMD7, VVMD25, VVMD27, VVMD31, VrZAG62 and VrZAG79) in order to evaluate their genetic diversity and relationships. According to their unique genotype at SSR loci finally 56 varieties were found. Interesting cases of synonymy, i.e. Greco di Tufo and Asprinio, Palummina and Piedirosso, and homonymy were disclosed. Pairwise genetic distances were calculated between all cultivars. Clustering of cultivars did not reflect their current distribution and this suggests that grape cultivars of Campania might have been introduced from various and distinct geographic areas

Therapeutic use exemption

Football players who have either physical symptoms or disease after injury may need to be treated with specific medicines that are on the list of prohibited substances. Therapeutic use exemption may be granted to such players, in accordance with strictly defined criteria—these are presented in this article. Procedures of how to request for an abbreviated or a standard therapeutic use exemption are explained, and data on therapeutic use exemptions (UEFA and FIFA, 2004 and 2005) are also presented

The parentage of 'Sangiovese', the most important Italian wine grape

A previous microsatellite study pointed out a possible parent-offspring relationship between 'Sangiovese', the most widespread red grape cultivar in Italy, and 'Ciliegiolo', an ancient Tuscan variety. Testing 'Sangiovese' as a parent of 'Ciliegiolo', we searched for the putative other parent in our extensive, private and standardized database, but we did not find any candidate. Testing 'Ciliegiolo' as a parent of 'Sangiovese', we found four candidate cultivars. After the analysis of 50 microsatellites, only one stood the paternity test and we established with a strong statistical support that 'Sangiovese' is a progeny of 'Ciliegiolo' and 'Calabrese di Montenuovo', an obscure grapevine from Campania, Italy. This cultivar does not have a registered name and is supposed to have been introduced from Calabria. Among 180 additional local grape cultivars from Calabria, Campania or Tuscany, we did not find any matching variety. As a consequence, we propose to adopt the name 'Calabrese di Montenuovo' for this grape cultivar. In addition, we found relatives of 'Sangiovese' and 'Calabrese di Montenuovo' in Calabria, thus strongly suggesting a Calabrian origin for 'Calabrese di Montenuovo' and indicating that 'Sangiovese' has ancestors and/or progenies in Tuscany and in Southern Italy.

A positive interaction between inhibitors of protein synthesis and cefepime in the fight against methicillin-resistant Staphylococcus aureus.

Quinupristin-dalfopristin (Q-D) synergizes with cefepime for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). Here, we studied whether the synergism was restricted to MRSA and if it extended to non-beta-lactam cell wall inhibitors or to other inhibitors of protein synthesis. Three MRSA and two methicillin-susceptible S. aureus (MSSA) strains were tested, including an isogenic pair of mecA (-)/mecA (+) S. aureus Newman. The drug interactions were determined by fractional inhibitory concentration (FIC) indices and population analysis profiles. The antibacterial drugs that we used included beta-lactam (cefepime) and non-beta-lactam cell wall inhibitors (D-cycloserine, fosfomycin, vancomycin, teicoplanin), inhibitors of protein synthesis (Q-D, erythromycin, chloramphenicol, tetracycline, linezolid, fusidic acid), and polynucleotide inhibitors (cotrimoxazole, ciprofloxacin). The addition of each protein inhibitor to cefepime was synergistic (FIC ≤ 0.5) or additive (FIC &gt; 0.5 but &lt; 1) against MRSA, but mostly indifferent against MSSA (FIC ≥ 1 but ≤ 4). This segregation was not observed after adding cotrimoxazole or ciprofloxacin to cefepime. Population analysis profiles were performed on plates in the presence of increasing concentrations of the cell wall inhibitors plus 0.25 × minimum inhibitory concentration (MIC) of Q-D. Cefepime combined with Q-D was synergistic against MRSA, but D-cycloserine and glycopeptides were not. Thus, the synergism was specific to beta-lactam antibiotics. Moreover, the synergism was not lost against fem mutants, indicating that it acted at another level. The restriction of the beneficial effect to MRSA suggests that the functionality of penicillin-binding protein 2A (PBP2A) was affected, either directly or indirectly. Further studies are necessary in order to provide a mechanism for this positive interaction

Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci.

OBJECTIVES: Daptomycin was tested in vitro and in rats with experimental endocarditis against the ampicillin-susceptible and vancomycin-susceptible Enterococcus faecalis JH2-2, the vancomycin-resistant (VanA type) mutant of strain JH2-2 (strain JH2-2/pIP819), and the ampicillin-resistant and vancomycin-resistant (VanB type) Enterococcus faecium D366. METHODS: Rats with catheter-induced aortic vegetations were treated with doses simulating intravenously kinetics in humans of daptomycin (6 mg/kg every 24 h), amoxicillin (2 g every 6 h), vancomycin (1 g every 12 h) or teicoplanin (12 mg/kg every 12 h). Treatment was started 16 h post-inoculation and continued for 2 days. RESULTS: MICs of daptomycin were 1, 1 and 2 mg/L, respectively, for strains JH2-2, JH2-2/pIP819 and D366. In time-kill studies, daptomycin showed rapid (within 2 h) bactericidal activity against all strains. Daptomycin was highly bound to rat serum proteins (89%). In the presence of 50% rat serum, simulating free concentrations, daptomycin killing was maintained but delayed (6-24 h). In vivo, daptomycin treatment resulted in 10 of 12 (83%), 9 of 11 (82%) and 11 of 12 (91%) culture-negative vegetations in rats infected with strains JH2-2, JH2-2/pIP819 and D366, respectively (P &lt; 0.001 compared to controls). Daptomycin efficacy was comparable to that of amoxicillin and vancomycin for susceptible isolates. Daptomycin, however, was significantly (P &lt; 0.05) more effective than teicoplanin against the glycopeptide-susceptible strain JH2-2 and superior to all comparators against resistant isolates. CONCLUSIONS: These results support the use of the newly proposed daptomycin dose of 6 mg/kg every 24 h for treatment of enterococcal infections in humans